Benign Prostatic Hyperplasia Case Study
Benign prostatic hyperplasia (BPH), erectile dysfunction, and prostate cancer are the three major medical conditions affecting male GU.
Benign prostatic hyperplasia (BPH), the prostate gland becomes enlarged which cause urinary dysfunction. It affects the GU in three ways, histologic prostatic hyperplasia, increase in outflow resistance, and bladder muscle obstruction. This is due because prostate growth function with androgen 5 alpha dihydrotestosterone. Treatment includes: alpha 1 adrenergic receptor blockers such ,as tamulosin, which decreases sympathetic tone and relax urethral stricture, by blocking alpha 1 adrenergic receptor (Edmunds, & Mayhew 2014). 5 alpha reductase inhibitors such as finasteride are also helpful in reducing the
size of the prostate gland by blocking the exchange of testosterone to dihydrotestosterone which is the main androgen used for prostate growth (Edmunds, & Mayhew 2014).
Erectile dysfunction (ED), is the incapability to maintain an erect penis to allow sexual intercourse. The cuases can be psychological, hormonal, neural, and vascular. The sympathetic (adrenergic) and parasympathetic (cholinergic) system are involved (Edmunds, & Mayhew 2014). Treatmet include, oral PDE5 inhibitors, such as sildenafil, inhibits cGMP which increases blood flow.
Benign prostatic hyperplasia (BPH), the prostate gland becomes enlarged which cause urinary dysfunction. It affects the GU in three ways, histologic prostatic hyperplasia, increase in outflow resistance, and bladder muscle obstruction. This is due because prostate growth function with androgen 5 alpha dihydrotestosterone. Treatment includes: alpha 1 adrenergic receptor blockers such ,as tamulosin, which decreases sympathetic tone and relax urethral stricture, by blocking alpha 1 adrenergic receptor (Edmunds, & Mayhew 2014). 5 alpha reductase inhibitors such as finasteride are also helpful in reducing the
size of the prostate gland by blocking the exchange of testosterone to dihydrotestosterone which is the main androgen used for prostate growth (Edmunds, & Mayhew 2014).
Erectile dysfunction (ED), is the incapability to maintain an erect penis to allow sexual intercourse. The cuases can be psychological, hormonal, neural, and vascular. The sympathetic (adrenergic) and parasympathetic (cholinergic) system are involved (Edmunds, & Mayhew 2014). Treatmet include, oral PDE5 inhibitors, such as sildenafil, inhibits cGMP which increases blood flow.